Cellular replacement via differentiation into neuron, astrocyte, or oligodendrocyte

The term "Cellular replacement via differentiation into neurons/astrocytes/oligodendrocytes" refers to a therapeutic strategy rather than a discrete molecular target. This approach involves the use of neural stem cells (NSCs) or neural progenitor cells that are induced to differentiate into specific central nervous system cell types—neurons, astrocytes, and oligodendrocytes—to replace lost or damaged brain tissue in neurodegenerative diseases such as Parkinson’s disease and Huntington’s disease. The success of this strategy depends on the ability to guide transplanted NSCs toward desired lineages and ensure their integration with host tissue. While various growth factors and signaling pathways regulate these processes—including SUMOylation/Hippo pathway modulation—there is no single receptor or molecule that constitutes a canonical drug target for "cellular replacement." Instead, it is an outcome achieved by manipulating multiple molecular targets within NSCs using cocktails of small molecules or proteins designed to promote specific patterns of differentiation[1][2][3][5]. **Note:** This entry does not correspond to a single molecule/receptor but describes a complex biological process involving multiple targets. Therefore, it should not be considered a canonical therapeutic target in the same sense as an enzyme or receptor protein.

Other names

Cell replacement therapyNeural stem cell differentiationNSC-mediated cellular replacementNeuronal/glial lineage differentiation

Induction of neural stem/progenitor cell differentiation into neurons, astrocytes, or oligodendrocytes[1][3]